Biogen Is Faulted on Its Sale Process
121287
The investor Carl C. Icahn said he was trying to get three supporters elected to the board of the biotechnology firm Biogen Idec because of concerns over the sales process.
732695
The stock of biotechnology company Biomira (Nasdaq: BIOM), a research and development company specializing in cancer, shot up 146% (to $3.77 a share) from yesterday&#39;s closing price after the company
176562
By Karen Attwood  The Dutch healthcare and chemicals group Akzo Nobel ditched plans to float its biopharmaceutical division in favour of a sale yesterday, triggering speculation it would next make a move on the chemicals group Imperial Chemical Industries.
463623
James C. Mullen,Biogen Idec Inc.Chief executive For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights of 2006. Chief executive James C. Mullen recently spoke with Globe reporter Jeffrey Krasner about the company's progress and the challenges posed by the 2006 election.
238313
A new study shows raises questions about the straying of plants altered through biotechnology and that could hurt the efforts of two companies to win approval for the first bioengineered grass.
305997
The Securities and Exchange Commission is scrutinizing biotechnology companies as part of a wider effort to ensure that companies don&#39;t mislead investors
708021
The pharma gives us its quest for bidders.
255760
Biogen Idec Inc., of Cambridge, had a remarkable 2004. Biogen had just finalized its $6.4 billion merger with Idec Corp., of San Diego, when it got word the Food and Drug Administration would consider its new multiple sclerosis drug on the basis of interim trial data, accelerating the approval timetable by a year. The company scrambled, applied on May 25, ...
462762
Biopure Corp. is running out of money -- again. Recent regulatory filings, including one yesterday, show the Cambridge blood-substitute developer seeking the financial flexibility it says it will need to keep operating after January. That's when it expects to use up the $7 million it raised through a stock sale in September.
565353
If Biogen Idec Inc. is sold to a pharmaceuticals giant, as many biotech industry observers expect, it could spell the loss of yet another major corporate headquarters in Massachusetts, a blow to the state's prestige.
447760
Hard-earned tips from a biotech investor.
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
403625
Be very wary of biotech IPOs from companies lacking drugs.
217834
Two former sales representatives for Amgen Inc. are suing the biotech company, alleging it pushed its sales force to search doctor's confidential medical records for potential patients to boost sales of a drug used to treat psoriasis.
320472
Fool Paul Elliott takes a chance on biotech -- with somebody else's money.
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
82904
SHANGHAI -- Looking at the facts, the past year seems to have been disastrous for Worldbest Pharmaceutical.  First, there were reports of accounting irregularities and exaggerated profit. Half the managers were fired. Then, in the summer, six people died and at least 80 fell ill after receiving an antibiotic injection manufactured by a subsidiary. Most recently, the company warned investors that it was likely to report its third consecutive year of losses....